Grace Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed Jun 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Jun 18, 2026
GRCE$1.86-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Cash Flows
| Year EndedMarch 31, 2026 | Year Ended March 31, 2025 | |
|---|---|---|
| (Expressed in thousands) | $ | $ |
| Cash flows from operating activities: | ||
| Net loss | (7,793) | (9,568) |
| Adjustments: | ||
| Depreciation expense | 7 | 7 |
| Loss on disposal | — | 2 |
| Stock-based compensation | 798 | 730 |
| Change in fair value of derivative warrant liabilities | (900) | (3,218) |
| Deferred income tax benefit | (1,700) | (3,199) |
| Changes in operating assets and liabilities: | ||
| Receivables | 106 | 596 |
| Prepaid expenses | 70 | (170) |
| Trade and other payables | 543 | (84) |
| Net cash used in operating activities | (8,869) | (14,904) |
| Cash flows from investing activities: | ||
| Maturity of short-term investments | — | 15 |
| Purchase of short-term investments | — | (15) |
| Net cash provided by investing activities | — | — |
| Cash flows from financing activities: | ||
| Gross proceeds from issuance of common stock and warrants from private placement | — | 14,999 |
| Stock issuance costs | (327) | (967) |
| Proceeds from issuance of common stock from common warrant exercise | 4,040 | — |
| Net cash provided by financing activities | 3,713 | 14,032 |
| Net decrease in cash and cash equivalents | (5,156) | (872) |
| Cash and cash equivalents, beginning of year | 22,133 | 23,005 |
| Cash and cash equivalents, end of year | 16,977 | 22,133 |
| Cash and cash equivalents are comprised of: | ||
| Cash | 1,307 | 830 |
| Cash equivalents | 15,670 | 21,303 |
| Supplemental schedule of non-cash financing activities are comprised of: | ||
| Issuance costs in accounts payable | — | 327 |
| Settlement of derivative warrant liability | 241 | — |
(Formerly ACASTI PHARMA, INC.)
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.